Numerous studies, particularly in areas including myocardial infarction (MI), as well as heart failure, have illuminated the crucial role of interfering with the NLRP3 pathway in mediating therapeutic effects through the ANS (13). This evidence concerns the gene NLRP3 and myocardial infarction.